Primarily used in the production of alcoholic beverages, especially beer, hops represent another large market for CELEXT07 in addition to cannabis.
MONTREAL, May 16, 2019 /CNW/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce the results from research on the use of its proprietary CELEXT07 bio-defense stimulant plant extract on hops plants, conducted in collaboration with McGill University.
Global hops production is expected to grow by 3.3% to 122,767 metric tons in 2019 (Source: IHGC - Economic Commission Summary Reports, April 26, 2019). Hops production in the United States alone reached a record high of US$618 million in 2017, up 24% from US$498 million in 2016 (Source: U.S. Department of Agriculture). The global hops market is driven by increasing demand for hops in alcoholic beverages, medicinal drugs and cosmetic formulations. Over the next five years, increased demand for various flavours in beer such as pilsner or lager and the rise in popularity for hop-based craft beer are major factors that will significantly fuel the growth of the global hops market (Source: Persistence Market Research).
The objective of the current series of tests was to measure CELEXT07's efficacy in suppressing and preventing diseases on hops plants. Hops is a genus belonging to the same taxonomic family as cannabis. Mondias' latest experiments on cannabis and hops served as proof-of-concept of the efficacy of the Company's botanicals in plant protection and increasing plant survival by eliciting induced resistance.
Summary of the test results:
- Foliar applications of CELEXT07 bio-defense stimulant extract were very effective in suppressing grey mould (caused by Botrytis cinerea) infections on hops, with decreases of 86% in disease severity and 67% in disease incidence.
- A scheduled dose split over three days for the soil drench application of CELEXT07 also proved effective for the prevention/suppression of grey mould on hops, with decreases of 31% in disease severity and up to 50% in disease incidence.
- Foliar and soil drench application of CELEXT07 did not have any phytotoxic effect on hops.
"These latest results continue to confirm that CELEXT07 is very effective in suppressing and preventing a wide range of fungal and bacterial pathogens, and has applications in more than one large market," said Jean-Philippe Gravel, Chief Executive Officer of Mondias. "As mentioned in our last release, Mondias has secured the production capacity needed to meet demand from potential clients. CELEXT07 is ready to market and we are presently looking at selling our product through various sales channels and markets, including the agriculture, horticulture, cannabis and hops markets."
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the Company's inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company's research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.
For further information: Mondias Natural Products Inc.: Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569, firstname.lastname@example.org; L. Derek Lindsay, Vice President, Corporate Development, 514-594-2372, email@example.com